CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation
publication date: Jan 14, 2022
CARsgen Therapeutics, a Shanghai CAR-T-company, was granted Regenerative Medicine Advanced Therapy (RMAT) designation in the US for CT041, an autologous CAR T-cell product. CT041 is being developed for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) with a Claudin18.2-positive tumor. The RMAT designation means CT041 has the benefits of Fast Track and Breakthrough Therapy designations. CT041 is the only CLDN18.2-targeted CAR T-cell candidate currently with IND approvals in the US, China and Canada. More details....
Stock Symbol: (HK: 2171)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.